Deep Apple and Novo Nordisk Partner on Cardiometabolic Drug Discovery

Deep Apple Therapeutics has announced a collaboration with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases, including obesity. Announced in a press release, the partnership aims to create first-in-class small molecule therapeutics targeting a novel non-incretin GPCR.

Under the agreement, Deep Apple will utilize its proprietary drug discovery platform, which integrates machine learning and cryo-electron microscopy, to identify and optimize compounds. Novo Nordisk will have exclusive global rights to develop, manufacture, and commercialize the resulting products.

Deep Apple is eligible to receive up to $812 million, including an upfront payment, research costs, and milestone payments, along with potential royalties on future sales. The collaboration will see both companies working together on the research plan, with Novo Nordisk taking over before the start of IND-enabling studies.